Novo Nordisk (NVO)
(Delayed Data from NYSE)
$118.01 USD
-1.06 (-0.89%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $117.96 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.01 USD
-1.06 (-0.89%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $117.96 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth A Momentum B VGM
Zacks News
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
by Kinjel Shah
FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $144.49, denoting a +0.57% change from the preceding trading day.
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
by Zacks Equity Research
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day.
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
by Zacks Equity Research
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?
by Kinjel Shah
Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales of the blockbuster drug will rise further.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the most recent trading session, Novo Nordisk (NVO) closed at $140.99, indicating a +0.13% shift from the previous trading day.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Take the Zacks Approach to Beat the Markets: Snap, Naspers, e.l.f. Beauty in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $142.50, moving +0.01% from the previous trading session.
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week.
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
by Zacks Equity Research
Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Macy's and Five Below have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Macy's and Five Below have been highlighted as Zacks Bull and Bear of the Day
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, TotalEnergies, U.S. Bancorp and Flanigan's
by Zacks Equity Research
Novo Nordisk, TotalEnergies, U.S. Bancorp and Flanigan's are included in this Analyst Blog.
Top Analyst Reports for Novo Nordisk, TotalEnergies & U.S. Bancorp
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), TotalEnergies SE (TTE) and U.S. Bancorp (USB), as well as a micro-cap stock Flanigan's Enterprises, Inc. (BDL).
ECB Rate Cut Propels European Markets: 3 Must-Watch Stocks
by Tirthankar Chakraborty
Historic ECB rate cut bolstered European stocks, which calls for keeping a tab on Siemens (SIEGY), ASML Holding (ASML) and Novo Nordisk (NVO) for solid growth.
New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.